
|Articles|July 4, 2020
- June 2020
- Volume 3
- Issue 2
Hereditary Angioedema: Management Updates for the Specialty Pharmacist
This continuing education activity is supported by an educational grant from Takeda.
Advertisement
THIS ACTIVITY IS SUPPORTED BY AN EDUCATIONAL GRANT FROM TAKEDA.
FACULTY
Melanie B. Radi, PharmD, CSP
Manager, Clinical Programs Specialty Clinical Services
AllianceRx Walgreens Prime
Pittsburgh, Pennsylvania
At the completion of this activity, the participant will be able to:
- Characterize the diagnosis and background of hereditary angioedema (HAE) and the significance of early intervention
- Examine the clinical data of FDA-approved agents and emerging therapies for acute treatment and prophylaxis of HAE
- Explore the need for individualized treatment and the role of the specialty pharmacist in patient education for effective HAE management
TARGET AUDIENCE: Pharmacists
ACTIVITY TYPE: Application
RELEASE DATE: May 15, 2020
EXPIRATION DATE: May 15, 2021
ESTIMATED TIME TO COMPLETE ACTIVITY: 2.0 hours
FEE: This lesson is offered for free at
Articles in this issue
almost 6 years ago
CIDP Care: A Patient and Clinical Experts Weigh Inalmost 6 years ago
JAK Inhibitors Are Important Tools for Patients With Myelofibrosisalmost 6 years ago
The Multidisciplinary Team Improves Cystic Fibrosis OutcomesAdvertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
World Schizophrenia Day: One Pharmacist's Vision for Safer Schizophrenia Care
2
Retatrutide Delivers Bariatric-Level Weight Loss in Pivotal Phase 3 TRIUMPH-1 Trial
3
Early Oral Antiviral Use Associated With Lower Risk of Post–COVID-19 Condition, Study Finds
4
From GLP-1s to Vaccines, APhA 2026 Showcased the Modern Clinical Pharmacist
5





































































































































